CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL[1].
CP-609754 (CP-609,754) is a reversible inhibitor of farnesyltransferase with a slow on/off rate. CP-609,754 inhibits farnesylation (IC50=1.72 ng/mL) of mutant H-Ras in 3T3 H-ras (61L)-transfected cell lines with SDS-PAGE analysis of [35S]methionine-labeled material[1].CP-609754 is competitive for the prenyl acceptor (H-Ras protein) and noncompetitive for the prenyl donor farnesyl PPI. CP-609754 interacts with the farnesyltransferase-farnesyl PPI complex and competes for the binding of the Ras protein. CP-609754 selectively inhibits farnesylation of both H- and K-Ras proteins in 3T3 transfectants[1].
CP-609754 (CP-609,754) has antitumor activity against 3T3 H-ras (61L) tumors in vivo[1].With twice daily oral dosing of CP-609754, tumor regression is achieved with a dose of 100 mg/kg; the ED50 for tumor growth inhibition is 28 mg/kg[1]. With continuous i.p. infusion of CP-609754, tumor growth is inhibited by >50%, and tumor farnesyltransferase activity inhibited by >30% in mice in which the plasma concentration of CP-609754 is maintained above 118 ng/mL[1].
[1]. Stacy L Moulder, et al. A phase I open label study of the farnesyltransferase inhibitor CP-609,754 in patients with advanced malignant tumors. Clin Cancer Res. 2004 Nov 1;10(21):7127-35.
關(guān)鍵字: CP-609754;OSI754;
德陽思諾生物科技有限公司坐落于德陽九為藍谷生物醫(yī)藥科技產(chǎn)業(yè)園,是一家專業(yè)的有機化合物制造商,專業(yè)為客戶提供醫(yī)藥中間體、有關(guān)物質(zhì)以及小分子抑制劑試劑,并從事原料藥合成工藝技術(shù)開發(fā)和轉(zhuǎn)讓,以及原料藥有關(guān)物質(zhì)的分離和純化及結(jié)構(gòu)確證。擅長無水無氧及超低溫反應(yīng)。我們有專業(yè)的團隊和成熟的技術(shù),有著高端的生產(chǎn)設(shè)備和檢測體系,已經(jīng)與行業(yè)領(lǐng)導(dǎo)企業(yè)建立了密切的產(chǎn)品和技術(shù)合作關(guān)系,也期待與您開啟新的合作。[